Literature DB >> 14691055

Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor.

Christopher J Langmead1, Jeffrey C Jerman, Stephen J Brough, Claire Scott, Rod A Porter, Hugh J Herdon.   

Abstract

1. This study characterises the binding of a novel nonpeptide antagonist radioligand, [(3)H]SB-674042 (1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone), to the human orexin-1 (OX(1)) receptor stably expressed in Chinese hamster ovary (CHO) cells in both a whole cell assay and in a cell membrane-based scintillation proximity assay (SPA) format. 2. Specific binding of [(3)H]SB-674042 was saturable in both whole cell and membrane formats. Analyses suggested a single high-affinity site, with K(d) values of 3.76+/-0.45 and 5.03+/-0.31 nm, and corresponding B(max) values of 30.8+/-1.8 and 34.4+/-2.0 pmol mg protein(-1), in whole cell and membrane formats, respectively. Kinetic studies yielded similar K(d) values. 3. Competition studies in whole cells revealed that the native orexin peptides display a low affinity for the OX(1) receptor, with orexin-A displaying a approximately five-fold higher affinity than orexin-B (K(i) values of 318+/-158 and 1516+/-597 nm, respectively). 4. SB-334867, SB-408124 (1-(6,8-difluoro-2-methyl-quinolin-4-yl)-3-(4-dimethylamino-phenyl)-urea) and SB-410220 (1-(5,8-difluoro-quinolin-4-yl)-3-(4-dimethylamino-phenyl)-urea) all displayed high affinity for the OX(1) receptor in both whole cell (K(i) values 99+/-18, 57+/-8.3 and 19+/-4.5 nm, respectively) and membrane (K(i) values 38+/-3.6, 27+/-4.1 and 4.5+/-0.2 nm, respectively) formats. 5. Calcium mobilisation studies showed that SB-334867, SB-408124 and SB-410220 are all functional antagonists of the OX(1) receptor, with potencies in line with their affinities, as measured in the radioligand binding assays, and with approximately 50-fold selectivity over the orexin-2 receptor. 6. These studies indicate that [(3)H]SB-674042 is a specific, high-affinity radioligand for the OX(1) receptor. The availability of this radioligand will be a valuable tool with which to investigate the physiological functions of OX(1) receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14691055      PMCID: PMC1574197          DOI: 10.1038/sj.bjp.0705610

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  SB-334867-A: the first selective orexin-1 receptor antagonist.

Authors:  D Smart; C Sabido-David; S J Brough; F Jewitt; A Johns; R A Porter; J C Jerman
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  Orexins: a new family of neuropeptides.

Authors:  D Smart
Journal:  Br J Anaesth       Date:  1999-11       Impact factor: 9.166

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR.

Authors:  D Smart; J C Jerman; S J Brough; S L Rushton; P R Murdock; F Jewitt; N A Elshourbagy; C E Ellis; D N Middlemiss; F Brown
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

6.  1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.

Authors:  R A Porter; W N Chan; S Coulton; A Johns; M S Hadley; K Widdowson; J C Jerman; S J Brough; M Coldwell; D Smart; F Jewitt; P Jeffrey; N Austin
Journal:  Bioorg Med Chem Lett       Date:  2001-07-23       Impact factor: 2.823

7.  The SK-N-MC cell line expresses an orexin binding site different from recombinant orexin 1-type receptor.

Authors:  Heike A Wieland; Richard M Söll; Henri N Doods; Dirk Stenkamp; Rudolf Hurnaus; Bärbel Lämmle; Annette G Beck-Sickinger
Journal:  Eur J Biochem       Date:  2002-02

8.  Sensitivity of orexin-A binding to phospholipase C inhibitors, neuropeptide Y, and secretin.

Authors:  J K Kane; H Tanaka; S L Parker; M Yanagisawa; M D Li
Journal:  Biochem Biophys Res Commun       Date:  2000-06-16       Impact factor: 3.575

9.  The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats.

Authors:  D C Piper; N Upton; M I Smith; A J Hunter
Journal:  Eur J Neurosci       Date:  2000-02       Impact factor: 3.386

10.  Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin.

Authors:  A N van den Pol; X B Gao; K Obrietan; T S Kilduff; A B Belousov
Journal:  J Neurosci       Date:  1998-10-01       Impact factor: 6.167

View more
  38 in total

Review 1.  Chemistry and biology of orexin signaling.

Authors:  Thomas Kodadek; Di Cai
Journal:  Mol Biosyst       Date:  2010-06-07

2.  Intramolecular fluorescence resonance energy transfer (FRET) sensors of the orexin OX1 and OX2 receptors identify slow kinetics of agonist activation.

Authors:  Tian-Rui Xu; Richard J Ward; John D Pediani; Graeme Milligan
Journal:  J Biol Chem       Date:  2012-03-02       Impact factor: 5.157

3.  Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.

Authors:  Richard J Ward; John D Pediani; Graeme Milligan
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 4.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

5.  Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A.

Authors:  Richard J Ward; John D Pediani; Graeme Milligan
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

6.  Orexin receptor subtype activation and locomotor behaviour in the rat.

Authors:  W K Samson; S L Bagley; A V Ferguson; M M White
Journal:  Acta Physiol (Oxf)       Date:  2009-11-04       Impact factor: 6.311

7.  The orexin-1 receptor antagonist SB-334867 decreases sympathetic responses to a moderate dose of methamphetamine and stress.

Authors:  Daniel E Rusyniak; Dmitry V Zaretsky; Maria V Zaretskaia; Pamela J Durant; Joseph A DiMicco
Journal:  Physiol Behav       Date:  2012-02-14

Review 8.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

9.  Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.

Authors:  Jie Yin; Kerim Babaoglu; Chad A Brautigam; Lindsay Clark; Zhenhua Shao; Thomas H Scheuermann; Charles M Harrell; Anthony L Gotter; Anthony J Roecker; Christopher J Winrow; John J Renger; Paul J Coleman; Daniel M Rosenbaum
Journal:  Nat Struct Mol Biol       Date:  2016-03-07       Impact factor: 15.369

Review 10.  Therapeutics development for addiction: Orexin-1 receptor antagonists.

Authors:  David A Perrey; Yanan Zhang
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.